This week, we dissect the critical new amendment to Brazil's RDC 657 software regulations, a move by ANVISA that specifically targets AI and machine learning devices. The update introduces complex new requirements for clinical validation, post-market changes, and cybersecurity, significantly raising the bar for market entry.

We explore what these changes mean for MedTech manufacturers, why Brazil is becoming one of the most demanding markets for digital health, and how companies can adapt their strategies to succeed.

**Case Study:**

Imagine your AI-powered diagnostic software, already successful in Europe and the US, is ready for its Brazilian launch. Suddenly, ANVISA's new amendment invalidates your entire clinical data package and demands a brand-new, localized study. How do you manage this unexpected, multi-million dollar roadblock without abandoning Latin America's largest market?

**Key Takeaways:**

- Does my AI software now need a separate validation dossier specifically for the Brazilian population?

- What is a "Pre-approved Change Plan" and how do I submit one to ANVISA for my adaptive algorithm?

- Are my current cybersecurity measures compliant with the newly mandated international standards?

- How can I leverage my existing clinical data to meet the new local requirements without starting from scratch?

- What are the new post-market surveillance duties for AI software that learns continuously?

- Will this amendment affect the registration timeline for my non-AI software products as well?

Navigating complex regulatory shifts like these is what we do best. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise in over 30 markets, including Brazil. We use advanced AI and data tools to streamline your path to market access. Don't let regulatory hurdles block your innovation.

Contact us at [email protected] or visit https://pureglobal.com/ to learn more.